Posted by Michael Wonder on 03 Feb 2022
Lipocine announces its partner received FDA acceptance of NDA resubmission for Tlando
3 February 2022 - PDUFA target action date set for 28 March 2022.
Lipocine today announced that Antares Pharma issued a press release announcing that the U.S. FDA has accepted its new drug application resubmission for Tlando (testosterone undecanoate).
